(Z)-Leukadherin-1

(Z)-白细胞粘附素-1

Leukadherin 1 | SCHEMBL18301010 | HY-15701 | (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoicacid | 4-(5-{[(5Z)-3-benzyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}furan-2-yl)benzoic acid | 4-[5-[(Z)-(3-benzyl-

(Z)-Leukadherin-1

L646893-5mg

5mg

≥98%

-20°C储存

超低温冰袋运输

(Z)-Leukadherin-1 (ADH-503 free base) is an orally active and allosteric CD11b agonist. (Z)-Leukadherin-1 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhances dendritic cell responses In Vitro (Z)-Leukadherin-1 (ADH-503 free base; 4 μM; 8 days) reduces the numbers of total tumor-infiltrating CD11b + cells and subsets of CD11b + monocytes, granulocytes, eosinophils, and macrophages. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo (Z)-Leukadherin-1 (ADH-503 free base; oral gavage; 30, 60, or 120 mg/kg; twice a day for 60 days) delayes tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival . (Z)-Leukadherin-1 (oral gavage; 30, 100 mg/kg; twice a day; on days 1 and 5) has the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/ml and AUC0-t in the plasma of 6950 and 13962 ng.h/ml at 30 and 100 mg/kg dosing, respectively . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: KPC mice [p48-CRE/Lox-stop-Lox(LSL)-Kras G12D /p53 flox/flox ] Dosage: 30, 60, or 120 mg/kg Administration: Oral gavage; 60 days Result: Delayed tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival. Animal Model: Male rats Dosage: 30, 100 mg/kg (Pharmacokinetic Analysis) Administration: Oral gavage twice a day; on days 1 and 5 Result: Had the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/ml and AUC0-t in the plasma of 6950 and 13962 ng.h/ml at 30 and 100 mg/kg dosing, respectively. Form:Solid IC50& Target:CD11b

(Z)-Leukadherin-1（ADH-503 游离碱）是一种口服活性异构 CD11b 激动剂。(Z)-Leukadherin-1能使肿瘤相关巨噬细胞重新极化，减少肿瘤浸润性免疫抑制髓系细胞的数量，并增强肿瘤相关巨噬细胞的活性。

2055362-72-4

C22H15NO4S2

421.49 g/mol

5342077

C1=CC=C(C=C1)CN2C(=O)/C(=C/C3=CC=C(O3)C4=CC=C(C=C4)C(=O)O)/SC2=S

4-[5-[(Z)-(3-benzyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl]benzoic acid

1S/C22H15NO4S2/c24-20-19(29-22(28)23(20)13-14-4-2-1-3-5-14)12-17-10-11-18(27-17)15-6-8-16(9-7-15)21(25)26/h1-12H,13H2,(H,25,26)/b19-12-

AEZGRQSLKVNPCI-UNOMPAQXSA-N

C1=CC=C(C=C1)CN2C(=O)C(=CC3=CC=C(O3)C4=CC=C(C=C4)C(=O)O)SC2=S

2055362-72-4

leukadherin-1

DMSO : 4.55 mg/mL (10.80 mM; ultrasonic and warming and heat to 60°C) Methanol : <1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)

1

6

5

421.044 Da

421.044 Da

128.000 Ų

29

0

680

0

1

4.8

28009878